相关实验视频

Updated: Jun 25, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

统一的三糖纳米凝用于葡萄糖稳定

Ellie G Puente^1,2, Rajalakshmi P Sivasankaran^1,2, Daniele Vinciguerra^1,2

¹Department of Chemistry and Biochemistry, University of California, Los Angeles 607 Charles E. Young Drive East Los Angeles California 90095-1569 USA maynard@chem.ucla.edu.

RSC applied polymers

|May 27, 2024

概括

新的trehalose纳米凝改善了葡萄糖的稳定性和可溶性,用于糖尿病治疗. 这些新型纳米粒子为严重低血糖管理提供了有希望的解决方案,特别是冷藏.

科学领域:

生物材料科学生物材料科学
药物输送系统药物输送系统
内分泌学在内分泌学.

背景情况:

葡萄糖激素是提高血糖水平的关键激素,主要用于治疗1型糖尿病的严重低血糖症.
目前的葡萄糖配方在中性pH下稳定性和溶解性不佳,限制了它们的治疗应用.
基于纳米粒子的药物递送系统为提高治疗蛋白质的稳定性和有效性提供了潜在的解决方案.

研究的目的:

开发和描述基于三甲基酸盐的纳米颗粒,以改善葡萄糖素的配方.
为了评估葡萄糖加载纳米凝的稳定性,可溶性,毒性和有效性.
评估这些纳米凝在治疗应用中的潜力,特别是用于治疗低血糖症.

主要方法:

选择性修改24位的葡萄糖和囊,以对甲基酸聚合物进行共价附着.
使用PEG2000滴醇作为交叉连接剂形成均的纳米粒子.
在不同温度下使用尺寸均性,HPLC和 thioflavin T 试验评估DPBS 中的葡萄糖纳米凝的稳定性.
在实验室评估纳米凝毒性 (纤维细胞,红细胞) 和葡萄糖的疗效.

主要成果:

葡萄糖纳米凝表现出显著的稳定性,在-20°C和4°C下至少保持5个月的尺寸均性,在25°C下5天,在37°C下12小时以下.
通过HPLC和提奥夫拉T测定,证实葡萄糖在纳米颗粒中的完整性在低温下至少5个月,在室温下2天.
实验室研究表明,纳米凝对纤维细胞无毒,对红细胞无血溶性,而葡萄糖保持其生物活性.

结论:

三醇纳米凝有效地提高了葡萄糖在水溶液中的稳定性和可溶性.
开发的葡萄糖纳米凝表现出良好的安全性,并保持治疗疗效.
这些发现强调了三糖纳米凝作为葡萄糖的一个有前途的配方的潜力,特别是用于在降低温度下储存.

更多相关视频

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues

Rapid One-step Enzymatic Synthesis and All-aqueous Purification of Trehalose Analogues

Published on: February 17, 2017

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...